Insider Trading Alert - PRE, HSC And AMSG Traded By Insiders
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Crame.
Yesterday, March 4, 2015, 133 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $62.50 to $191,397,755.25.
Highlighted Stocks Traded by Insiders:
PartnerRe (PRE) - FREE Research Report
Miranthis Constantinos, who is Former President & CEO at PartnerRe, sold 1,700 shares at $114.23 on March 4, 2015. Following this transaction, the Former President & CEO owned 198,727 shares meaning that the stake was reduced by 0.85% with the 1,700-share transaction.
The shares most recently traded at $112.07, down $2.16, or 1.92% since the insider transaction. Historical insider transactions for PartnerRe go as follows:
- 4-Week # shares sold: 7,768
- 12-Week # shares sold: 7,768
- 24-Week # shares sold: 8,768
The average volume for PartnerRe has been 475,500 shares per day over the past 30 days. PartnerRe has a market cap of $5.4 billion and is part of the financial sector and insurance industry. Shares are down 1.6% year-to-date as of the close of trading on Wednesday.
PartnerRe Ltd., through its subsidiaries, provides reinsurance and certain specialty insurance services worldwide. The stock currently has a dividend yield of 2.46%. The company has a P/E ratio of 5.8. Currently, there are 2 analysts who rate PartnerRe a buy, 1 analyst rates it a sell, and 11 rate it a hold.
Exclusive Offer: Get the latest Stock Analysis on PRE - FREE
rates PartnerRe as a
. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels and increase in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full
from
now.
Harsco (HSC) - FREE Research Report
Minan Peter Francis, who is Chief Financial Officer at Harsco, bought 5,763 shares at $15.45 on March 4, 2015. Following this transaction, the Chief Financial Officer owned 19,461 shares meaning that the stake was boosted by 42.07% with the 5,763-share transaction.
The shares most recently traded at $16.18, up $0.73, or 4.51% since the insider transaction. Historical insider transactions for Harsco go as follows:
- 4-Week # shares bought: 25,000
- 12-Week # shares bought: 25,000
- 24-Week # shares bought: 25,000
The average volume for Harsco has been 607,700 shares per day over the past 30 days. Harsco has a market cap of $1.3 billion and is part of the basic materials sector and metals & mining industry. Shares are down 14.72% year-to-date as of the close of trading on Wednesday.
Harsco Corporation provides industrial services and engineered products worldwide. The company operates in three segments: Harsco Metals and Minerals, Harsco Rail, and Harsco Industrial. The stock currently has a dividend yield of 5.12%. Currently, there are no analysts who rate Harsco a buy, no analysts rate it a sell, and 3 rate it a hold.
Exclusive Offer: Get the latest Stock Analysis on HSC - FREE
rates Harsco as a
. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, generally high debt management risk, poor profit margins and generally disappointing historical performance in the stock itself. Get the full
from
now.
Amsurg (AMSG) - FREE Research Report
Eastridge Kevin Delon, who is Sr. VP of Finance, CAO at Amsurg, sold 8,999 shares at $60.43 on March 4, 2015. Following this transaction, the Sr. VP of Finance, CAO owned 39,588 shares meaning that the stake was reduced by 18.52% with the 8,999-share transaction.
The shares most recently traded at $61.56, up $1.13, or 1.84% since the insider transaction. Historical insider transactions for Amsurg go as follows:
- 4-Week # shares sold: 3,000
- 12-Week # shares sold: 3,000
- 24-Week # shares sold: 3,000
The average volume for Amsurg has been 464,000 shares per day over the past 30 days. Amsurg has a market cap of $2.9 billion and is part of the health care sector and health services industry. Shares are up 12.97% year-to-date as of the close of trading on Wednesday.
AmSurg Corp., through its subsidiaries, acquires, develops, and operates ambulatory surgery centers (ASC) in partnership with physicians in the United States. The company has a P/E ratio of 47.6. Currently, there are 8 analysts who rate Amsurg a buy, 1 analyst rates it a sell, and 1 rates it a hold.
Exclusive Offer: Get the latest Stock Analysis on AMSG - FREE
rates Amsurg as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, increase in net income and good cash flow from operations. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full
from
now.
null